


<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No.</b> MBM 1240	<b>Serial No.:</b> 09/927,110
	<b>Applicant:</b> ZHU et al	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 10, 2001	<b>Group Art Unit:</b> 1645

**RECEIVED**

**TECH CENTER 1600/2900**

**U.S. PATENT DOCUMENTS**


EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>JS</i>	AA	5,759,536	06/02/1998	Bellgrau and Duke	/	/	
<i>J</i>	AB	6,042,826	03/28/2000	Caligiuri, et al	/	/	
<i>J</i>	AC	6,046,310	04/04/2000	Queen et al.	/	/	

**FOREIGN PATENT DOCUMENTS**


EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
<i>JS</i>	AD	EP 0675200	04/10/95	EPO			
<i>JS</i>	AE	WO 95/32627	12/07/1995	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**


<i>JS</i>	AF	Ashany et al., "Th1 CD4+ Lymphocytes Delete Activated Macrophages Through the Fas/APO-1 Atigen Pathway" <i>Proc. Natl. Acad. Sci. USA.</i> <b>92: 11225-11229</b> , 1995
	AG	Batteux et al., "Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand" <i>J Immunol.</i> <b>162: 603-608</b> , 1999
	AH	Batteux et al., "Transgenic Expression of Fas Ligand on Thyroid Follicular Cells Prevents Autoimmune Thyroiditis" <i>J. Immunol.</i> <b>164: 1681-1688</b> , 2000
	AI	Bellegrau et al., "A Role for CD95 Ligand in Preventing Graft Rejection" <i>Nature</i> <b>377:630-632</b> , 1995
<i>J</i>	AJ	Bitter et al., "Expression and Secretion Vectors for Yeast" <i>Methods in Enzymol.</i> <b>153: 516-544</b> , 1987

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 6/12/03
--	-----------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No.</b> MBM 1240	<b>Serial No.:</b> 09/927,110
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Applicant:</b> ZHU et al	
	<b>Filing Date:</b> August 10, 2001	<b>Group Art Unit:</b> 1645

✓	AK	Brown and Savill, "Phagocytosis Triggers Macrophage Release of Fas Ligand and Induces Apoptosis of Bystander Leukocytes" <i>J. Immunol.</i> <b>162:480-485</b> , 1999
	AL	Brunner et al., "Cell-autonomous Fas (CD95)/Fas-ligand Interaction Mediates Activation-induced Apoptosis in T-cell hybridomas" <i>Nature</i> <b>373: 441-444</b> , 1995
	AM	Depraetere and Golstein, "Fas and other Death Signaling Pathways" <i>Semin Immunol.</i> <b>9: 93-107</b> , 1997
	AN	Dhein et al., "Autocrine T-cell Suicide Mediated by APO-1/(Fas/CD95)" <i>Nature</i> <b>373: 438-441</b> , 1995
	AO	French et al., "Fas and Fas Ligand in Embryos and adult Mice: Ligand Expression in Several Immune-privileged Tissues and Coexpression in Adult Tissues Characterized by Apoptotic Cell Turnover" <i>J. Cell Biol.</i> <b>133(2): 335-343</b> , 1996
	AP	Griffith et al., "Fas Ligand-Induced Apoptosis as a Mechanism of Immune privilege" <i>Science</i> <b>270: 1189-1192</b> , 1995
	AQ	Hunt et al., "Fas Ligand is Positioned in Mouse Uterus and Placenta to prevent Trafficking of Activated Leukocytes Between the Mother and the Conceptus" <i>J. Immunol.</i> <b>158:4122-4128</b> , 1997
	AR	Ju et al., "Fas(CD95)/FasL Interactions Required for Programmed Cell Death after T-cell Activation" <i>Nature</i> <b>373: 444-448</b> , 1995
	AS	Kiener et al., "Human Monocytic Cells Contain High Levels of Intracellular Fas Ligand" <i>J Immunol.</i> <b>159:1594-1598</b> , 1997
	AT	Kohji and Matsumoto, "Coexpression of Fas/FasL and Bax on Brain and Infiltrating T Cells in the Central Nervous System is Closely Associated with Apoptotic Cell Death During Autoimmune Encephalomyelitis" <i>J. Neuroimmunol.</i> <b>106:165-171</b> , 2000
✓	AU	Logan and Shenk, "Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late after Infection" <i>Proc. Natl. Acad. Sci USA.</i> <b>81(12): 3655-3659</b> , 1984



<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 8/12/03
--	-----------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No.</b> MBM 1240	<b>Serial No.:</b> 09/927,110
	<b>Applicant:</b> ZHU et al	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 10, 2001	<b>Group Art Unit:</b> FEB 06 2003 1645


**RECEIVED**

**TECH CENTER 1600/2900**

	AV	McCombe et al., "Apoptosis of VB8.2+ T lymphocytes in the Spinal Cord during Recovery from Experimental Autoimmune Encephalomyelitis Induced in Lewis Rats by Inoculation with Myelin Basic Protein" <i>J. Neuroimmunol Sci.</i> <b>139:1-6</b> , 1996
	AW	Ogasawara et al., "Lethal Effect of the Anti-Fas Antibody in Mice" <i>Nature</i> <b>364: 806-809</b> , 1993
	AX	Okamoto et al., "Induction of Apoptosis in the Rheumatoid Synovium by Fas Ligand Gene Transfer" <i>Gene Therapy</i> <b>5:331-338</b> , 1998
	AY	Okuda et al., "The Effect of Apoptosis Inhibitors on Experimental Autoimmune Encephalomyelitis: Apoptosis as a Regulatory Factor" <i>Biochem. Biophys. Res. Comm.</i> <b>267: 826-830</b> , 2000
	AZ	Okuda et al., "Interthecal Administration of Neutralizing Antibody Against Fas Ligand Suppresses the Progression of Experimental Autoimmune Encephalomyelitis" <i>Biochem. Biophys. Res. Comm.</i> <b>275:164-168</b> , 2000
	BA	Sabelko-Downes, et al., "Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergic Encephalomyelitis" <i>J. Exp. Med.</i> , <b>189 (8):1195-1205</b> , 1999
	BB	Takeda et al., "Protection of Islet Allografts Transplanted together with Fas Ligand Expressing Testicular Allografts" <i>Diabetologia</i> <b>41:315 - 321</b> , 1998
	BC	Uckan et al., "Trophoblasts Express Fas Ligand: A Proposed Mechanism for Immune Privilege in Placenta and Maternal Invasion" <i>Mol. Hum. Reprod</i> <b>3(8):655-662</b> , 1997
	BD	Watanabe et al., "Expression of Fas in B Cells of the Mouse Germinal Center and Fas-Dependent Killing of Activated B Cells" <i>Int. Immunol.</i> <b>7:1949-1956</b> , 1995
	BE	Wekerle et al., "Animal Models" <i>Ann Neurol.</i> <b>36: S47-S53</b> , 1994
	BF	White et al., "B Cell Apoptosis in the Central Nervous Systems in Experimental Autoimmune Encephalomyelitis: Roles of B cell CD95, CD 95L and Bcl-2 Expression" <i>J Autoimmune</i> <b>14: 195-204</b> , 2000

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 6/12/03
--	-----------------------------------



**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No.</b> MBM 1240	<b>Serial No.:</b> 09/927,110
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Applicant:</b> ZHU et al	
	<b>Filing Date:</b> August 10, 2001	<b>Group Art Unit:</b> 1645

**RECEIVED**

FEB 06 2003

TECH CENTER 1600/2900

	BG	Xerri, et al., " Fas Ligand is not only Expressed in Immune Privileged Human Organs but is also Coexpressed with Fas in Various Epithelial Tissues" <i>J. Clin. Mol. Pathol.</i> 50:87-91, 1997
	BH	Zhang et al., " Amelioration of Collagen-induced Arthritis by CD95 ( Apo-1/Fas)-Ligand gene Transfer" <i>J Clinical Invest.</i> 100: 1951-1957, 1997

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 6/12/03
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.